Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.84 |
| ▸ | FGFR1 | P11362 | 14/20 | 0.84 |
| ▸ | PDGFRB | P09619 | 14/20 | 0.84 |
| ▸ | RET | P07949 | 3/20 | 0.84 |
| ▸ | FLT3 | P36888 | 3/20 | 0.84 |
| ▸ | AURKA | O14965 | 2/20 | 0.84 |
| ▸ | FLT1 | P17948 | 2/20 | 0.84 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.84 |
| ▸ | STK3 | Q13188 | 2/20 | 0.84 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.84 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.84 |
| ▸ | GAK | O14976 | 1/20 | 0.84 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.84 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.84 |
| ▸ | LATS1 | O95835 | 1/20 | 0.84 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.84 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.84 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.84 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.84 |
| ▸ | STK4 | Q13043 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orantinib SCHEMBL134661 | 0.91 | FGFR1 (1.00) | KDRFGFR1PDGFRBRETFLT3 | |
| Orantinib SCHEMBL29354645 | 0.91 | FGFR1 (1.00) | KDRFGFR1PDGFRBRETFLT3 | |
| Orantinib SCHEMBL900355 | 0.91 | FGFR1 (1.00) | KDRFGFR1PDGFRBRETFLT3 | |
| Orantinib SCHEMBL134662 | 0.91 | FGFR1 (1.00) | KDRFGFR1PDGFRBRETFLT3 | |
| SCHEMBL26023377 | 0.88 | KDR (0.79) | KDRFGFR1PDGFRBRETFLT3 | |
| SCHEMBL13497857 | 0.88 | KDR (0.79) | KDRFGFR1PDGFRBRETFLT3 | |
| SCHEMBL25717271 | 0.88 | KDR (0.82) | KDRFGFR1PDGFRBRETFLT3 | |
| SCHEMBL16366587 | 0.86 | KDR (0.76) | KDRFGFR1PDGFRBRETFLT3 | |
| SCHEMBL12596436 | 0.85 | KDR (0.74) | KDRFGFR1PDGFRBRETFLT3 | |
| SCHEMBL13799829 | 0.85 | AURKA (0.68) | KDRFGFR1PDGFRBRETFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771698-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-8815241-B2 | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-26 | — | — | US | disclosed |
| US-20110293615-A1 | Use of Combination of Anti-Angiogenic Substance and c-kit Kinase Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-12-01 | — | — | US | disclosed |
| US-20100048890-A1 | CONJUGATED SMALL MOLECULES | DISCOVERX CORPORATION | 2010-02-25 | — | — | US | disclosed |
| US-20090053236-A1 | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048890-A1 | CONJUGATED SMALL MOLECULES | ERBB2, ALK, ACP1 | KDR 453/4885FGFR1 106/4885PDGFRB 560/4885 |
| US-20110293615-A1 | Use of Combination of Anti-Angiogenic Substance and c-kit Kinase Inhibitor | KIT, FLT4, KDR | KDR 3/4885FGFR1 393/4885PDGFRB 18/4885 |
| US-20090053236-A1 | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | KIT, FLT4, KDR | KDR 3/4885FGFR1 393/4885PDGFRB 18/4885 |
| US-11771698-B2 | Methods of treating cholangiocarcinoma | HCCS, PNLIP, LIPA | KDR 2368/4885FGFR1 1732/4885PDGFRB 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.